Suppr超能文献

比较当代美国经皮冠状动脉介入治疗患者与 ISCHEMIA 试验人群。

Comparison of Patients Undergoing Percutaneous Coronary Intervention in Contemporary U.S. Practice With ISCHEMIA Trial Population.

机构信息

Division of Cardiovascular Medicine, North Shore-Long Island Jewish Medical Centers, Northwell Health, Donald and Barbara Zucker School of Medicine New York at Hofstra/Northwell, Hempstead, New York, USA.

Division of Cardiovascular Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA; Penn Cardiovascular Outcomes, Quality, and Evaluative Research Center, Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

出版信息

JACC Cardiovasc Interv. 2021 Nov 8;14(21):2344-2349. doi: 10.1016/j.jcin.2021.08.047.

Abstract

OBJECTIVES

The study sought to assess the proportion of patients in modern U.S. interventional practice that fulfilled criteria for enrollment in the ISCHEMIA (International Study of Comparative Health Effectiveness With Medical and Invasive Approaches) trial.

BACKGROUND

The ISCHEMIA trial, which enrolled patients with stable ischemic heart disease (SIHD), showed that revascularization improved angina symptoms with little effect on death or myocardial infarction.

METHODS

A cross-sectional analysis of the National Cardiovascular Data Registry CathPCI Registry (v5.0), including 1,662 hospitals, was performed. Patients undergoing percutaneous coronary intervention (PCI) for SIHD in routine clinical practice meeting ISCHEMIA trial inclusion criteria and those that did not were evaluated.

RESULTS

During the study period, 388,212 patients underwent PCI for SIHD, comprising 41.88% of all patients undergoing PCI during the study period. Of these, 125,302 (32.28%; 13.52% of all patients undergoing PCI) met criteria for enrollment in the ISCHEMIA trial. Among SIHD patients that did not meet criteria, 71,852 (18.51%) had SIHD with high-risk features (35.2% left main disease, 43.7% left ventricular systolic dysfunction, 16.8% end-stage renal disease), 67,159 (17.3%) had SIHD with negative or low-risk functional testing, and 123,899 (31.92%) either had no stress testing or did not have ischemic burden reported. At the median hospital, 32.1% (interquartile range: 23.5%-40.6%) of SIHD patients met criteria for enrollment in the ISCHEMIA trial, with these patients experiencing lower unadjusted in-hospital mortality rate than comparator groups who met exclusion criteria for the trial (0.11%) (P < 0.01 for all comparisons).

CONCLUSIONS

Among contemporary U.S. patients undergoing PCI for SIHD, 32.28% clearly met enrollment criteria for the ISCHEMIA trial. There was significant variation among individual centers in the proportion of SIHD patients meeting criteria for the ISCHEMIA trial.

摘要

目的

本研究旨在评估在美国现代介入实践中,符合 ISCHEMIA(比较医学和介入方法对缺血效果的国际研究)试验入组标准的患者比例。

背景

ISCHEMIA 试验纳入了稳定性缺血性心脏病(SIHD)患者,结果显示血运重建改善了心绞痛症状,但对死亡或心肌梗死几乎没有影响。

方法

对国家心血管数据注册中心 CathPCI 注册中心(v5.0)进行了一项横断面分析,共包括 1662 家医院。评估了在常规临床实践中接受经皮冠状动脉介入治疗(PCI)治疗 SIHD 且符合 ISCHEMIA 试验纳入标准的患者和不符合标准的患者。

结果

在研究期间,388212 例患者因 SIHD 接受 PCI,占同期接受 PCI 的所有患者的 41.88%。其中,125302 例(32.28%;所有接受 PCI 的患者的 13.52%)符合 ISCHEMIA 试验的入组标准。在不符合标准的 SIHD 患者中,71852 例(18.51%)具有高危特征(35.2%的左主干病变、43.7%的左心室收缩功能障碍、16.8%的终末期肾病),67159 例(17.3%)具有阴性或低风险的功能检查结果,123899 例(31.92%)未进行应激试验或未报告缺血负荷。在中位数医院,32.1%(四分位间距:23.5%-40.6%)的 SIHD 患者符合 ISCHEMIA 试验的入组标准,这些患者的未调整住院死亡率低于试验排除标准的比较组(0.11%)(所有比较 P<0.01)。

结论

在美国现代接受 PCI 治疗 SIHD 的患者中,32.28%的患者显然符合 ISCHEMIA 试验的入组标准。个别中心符合 ISCHEMIA 试验标准的 SIHD 患者比例存在显著差异。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验